The fourth molybdenum containing enzyme mARC: cloning and involvement in the activation of N-hydroxylated prodrugs

…, H Hungeling, S Kanzow, J Kotthaus…

文献索引：Gruenewald, Sanja; Wahl, Bettina; Bittner, Florian; Hungeling, Helen; Kanzow, Stephanie; Kotthaus, Joscha; Schwering, Ulrike; Mendel, Ralf R.; Clement, Bernd Journal of Medicinal Chemistry, 2008 , vol. 51, # 24 p. 8173 - 8177

全文：HTML全文

被引用次数: 70

摘要

The recently discovered mammalian molybdoprotein mARC1 is capable of reducing N- hydroxylated compounds. Upon reconstitution with cytochrome b5 and b5 reductase, benzamidoxime, pentamidine, and diminazene amidoximes, N-hydroxymelagatran, guanoxabenz, and N-hydroxydebrisoquine are efficiently reduced. These substances are amidoxime/N-hydroxyguanidine prodrugs, leading to improved bioavailability compared ...